

Received: 13.11.2024

Accepted: 25.11.2024

Published: 18.04.2025

Maciej Porczyński, Elżbieta Woźniak, Elżbieta Jakubowska-Pietkiewicz

Vitamin K₂ levels in children and adolescents with bone fractures – a pilot study

Ocena stężenia witaminy K₂ u dzieci i nastolatków ze złamaniami kości – badanie pilotażowe

Department of Paediatrics, Neonatal Pathology and Bone Metabolic Diseases, Medical University of Lodz, Łódź, Poland

Correspondence: Maciej Porczyński, Department of Paediatrics, Neonatal Pathology and Bone Metabolic Diseases, Medical University of Lodz, Kościuszki 4, 90-419 Łódź, Poland,

e-mail: maciej.porczyński@umed.lodz.pl

 <https://doi.org/10.15557/PIMR.2025.0007>

ORCID iDs

1. Maciej Porczyński <https://orcid.org/0000-0002-4461-320X>

2. Elżbieta Woźniak <https://orcid.org/0000-0002-9629-2452>

3. Elżbieta Jakubowska-Pietkiewicz <https://orcid.org/0000-0002-5346-5229>

Abstract

Introduction and objective: In addition to coagulation, vitamin K₂ influences vascular calcification and skeletal mineral balance. Evaluation of its levels and setting reference ranges are mainly relevant for all populations at risk of osteoporosis. However, only few reports have focused on the developmental age population. The aim of this study was to assess vitamin K₂ levels in children with bone fractures. **Materials and methods:** The study group consisted of 145 children aged 5–17 years, hospitalised for suspected metabolic bone diseases. Patients were divided into three groups: healthy children ($n = 68$), children with osteogenesis imperfecta ($n = 29$), and children with traumatic fractures ($n = 48$). All children were assessed for physical development using established methods, and had their vitamin K₂ levels measured with immunoenzymatic assay (ELISA), using a SunRedBio kit (China). **Results:** The evaluated group of children showed normal somatic development. Children with osteogenesis imperfecta showed lower height and body weight compared to the other groups. Vitamin K₂ ranged from 0.90 to 12.46 ng/mL in 80% of healthy children. Low vitamin K₂ levels (2.7 ng/mL for osteogenesis imperfecta and 2.05 ng/mL for fractures) were found in groups 2 and 3, and did not differ statistically significantly between children considered healthy and patients with bone fractures, including those with osteogenesis imperfecta. **Conclusions:** Children with a history of bone fractures have vitamin K₂ levels within the reference ranges for this age group, suggesting that bone fractures in this group are not associated with vitamin K₂ deficiency.

Keywords: vitamin K₂, children, bone fracture

Streszczenie

Wprowadzenie i cel: Poza układem krzepnięcia witamina K₂ wpływa na procesy kalcyfikacji ścian naczyń krwionośnych i gospodarkę mineralną szkieletu. Oznaczanie jej stężenia i wyznaczanie norm referencyjnych dotyczy przede wszystkim populacji zagrożonych osteoporozą, a niewiele badań przeprowadzono z udziałem populacji wieku rozwojowego. Celem pracy była ocena stężenia witaminy K₂ u dzieci i nastolatków ze złamaniami kości. **Materiał i metody:** Grupę badaną stanowiło 145 dzieci w wieku 5–17 lat hospitalizowanych z powodu podejrzenia zaburzeń mineralizacji kości. Pacjentów podzielono na trzy grupy: dzieci z wrodzoną łamliwością kości ($n = 29$), dzieci z co najmniej dwoma złamaniami pourazowymi ($n = 48$) i dzieci zdrowe ($n = 68$). U wszystkich badanych przeprowadzono ocenę rozwoju fizycznego zgodnie z przyjętymi metodami i oceniono stężenie witaminy K₂ metodą immunoenzymatyczną (ELISA) z użyciem zestawu firmy SunRedBio (Chiny). **Wyniki:** Rozwój somatyczny ocenianej grupy dzieci był prawidłowy, u dzieci z wrodzoną łamliwością kości wykazano niższy wzrost i mniejszą masę ciała w porównaniu z pozostałymi grupami. Stężenie witaminy K₂ u 80% dzieci zdrowych wynosiło 0,90–12,46 ng/ml. Stężenia witaminy K₂ w grupach II i III były niskie – w grupie z łamliwością kości 2,7 ng/ml, a w grupie ze złamaniami 2,05 ng/ml – i nie różniły się istotnie statystycznie między dziećmi uznanymi za zdrowe a pacjentami ze złamaniami kości, w tym z wrodzoną łamliwością kości. **Wnioski:** Stężenie witaminy K₂ w badanej populacji dzieci i nastolatków ze złamaniami kości w wywiadzie mieściło się w granicach uznanych za referencyjne dla tej grupy wiekowej, co sugeruje, że u badanych złamania nie były związane z niedoborem tej witaminy.

Słowa kluczowe: witamina K₂, dzieci, złamania kości

INTRODUCTION

The involvement of vitamin K in body's mineral metabolism has aroused an increasing interest in the measurement of its various forms in multiple clinical conditions. In addition to coagulation processes, vitamin K₂ influences vascular calcification and skeletal mineral balance. Vitamin K₂ measurements and attempts at setting its reference values are primarily done in populations at risk of osteoporosis, and only few studies have been conducted in children and adolescents.

Many direct and indirect methods have been used for assessing vitamin K levels in the body. However, uniform standards are missing, which makes it difficult to accurately determine its optimal level and compare the results across different studies, which additionally use different measurement units⁽¹⁾.

According to Mager et al., indirect measurements are sensitive to errors and should therefore be used with caution^(2,3). Indirect methods include prothrombin time, serum uncarboxylated osteocalcin, matrix Gla protein and PIVKA-II, i.e. proteins induced by vitamin K deficiency, as well as urinary vitamin K metabolites (7C-aglycone and 5C-aglycone). Direct measurement of vitamin K and its metabolites is currently the preferred approach⁽⁴⁾. Direct methods for determining vitamin K in humans include high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection, HPLC with fluorescence detection, HPLC with electrochemical detectors (ECD), and liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry (LC-APCI-MS/MS), which shows the highest sensitivity⁽¹⁾.

Although vitamin K levels have been assessed by many authors using direct approaches, most of the studies have been conducted in adults. Tsugawa et al. determined the mean values of MK-4 and MK-7 (menaquinone with 4 and 7 prenyl units) at 0.07–0.1 ng/mL and 4.21–8.42 ng/mL, respectively, using LC-APCI-MS/MS in a group of women >30 years of age⁽⁵⁾. In 2018, Klapkova et al. used HPLC coupled with fluorescence detection (HPLC-FLD) in postmenopausal women, and determined the mean MK-4 and MK-7 at 0.433 ± 0.394 ng/mL and 1.002 ± 1.020 ng/mL, respectively⁽⁶⁾. Volkan et al. (2018), who used the Human Vitamin K₂ Elis immunological kit to determine vitamin K₂ in a group of children aged 8–14 years (with or without celiac disease), found that it was 2.64 ± 2.1 nmol/L⁽⁷⁾. In 2022, Du and Li showed that the median level of vitamin K₂ was 0.1 ng/mL (interquartile range P25, P75 – 0.1, 0.2) in children aged 1–14 years, using high-performance liquid chromatography tandem mass spectrometry⁽⁸⁾.

The aim of this study was to assess vitamin K₂ levels in children and adolescents with bone fractures.

MATERIALS AND METHODS

The study was conducted among 145 children aged 5–17 years, who were admitted to the Department of Paediatrics,

Neonatal Pathology and Bone Metabolic Diseases due to suspected bone mineralisation disorders after fractures or were considered healthy, with no history of chronic disorders. The participants were allocated into three groups: children with fractures in the course of congenital bone fragility in group 1 ($n = 29$), children with fractures without metabolic bone disease in group 2 ($n = 48$), and children considered healthy in group 3 (controls; $n = 68$). None of the children were supplemented with vitamin K prior to the study.

All patients had their medical history taken and underwent anthropometric measurements (height and weight, body mass index – BMI). Serum vitamin K₂ was also determined by enzyme-linked immunosorbent assay (ELISA) using a kit from SunRedBio (China). The sensitivity of the kit was 2.225 ng/mL.

R version 4.0.1. was used for statistical analysis. The study was approved by the Bioethics Committee at the Medical University of Lodz (no. RNN/116/17/KE).

RESULTS

No statistically significant differences were found between the three study groups in terms of age, BMI, BMI Z-score or body mass. For body height, it was shown that the groups differed significantly both in absolute and Z-score values. In the case of body weight, the difference between the groups was statistically significant only for the Z-score. Post-hoc analysis showed that group 1 was characterised by a significantly lower mean height and body mass than groups 2 and 3 (Tab. 1).

The analysis of vitamin K₂ levels across the groups is presented in Tab. 2.

Based on the mean and SD values for vitamin K₂ levels in group 3, a distribution curve was drawn and an asymmetric, right-sided distribution was obtained (Fig. 1). No extremely low vitamin K₂ levels were observed in this group. This was confirmed by the Shapiro–Wilk test for vitamin K₂ levels in this group ($p < 0.001$) (Fig. 1).

Data distribution other than normal distribution can be presented using deciles, which are a reference point for a given result against the background of the entire group. For this purpose, Tab. 3 presents a decile division for vitamin K₂ in group 3. It was found on its basis that after excluding 20% of children with extreme vitamin K₂ levels, the level ranged between 0.90 and 12.46 ng/mL in the remaining 80% of children.

Then, the levels of vitamin K₂ were assessed across the study groups. The median vitamin K₂ level was 2.05 ng/mL in group 2 and 2.30 ng/mL in group 3. No statistically significant difference in vitamin K₂ levels was confirmed between the two groups (median – MD = –0.25; 95% CI: –0.80, 0.40; $p = 0.575$) (Tab. 4).

The median vitamin K₂ level was 2.70 ng/mL in group 1 and 2.30 ng/mL in group 3. No statistically significant difference in vitamin K₂ levels was shown between the two groups (MD = 0.40; 95% CI: –0.50, 1.30, $p = 0.424$) (Tab. 5).


Variable	Total	Group 1	Group 2	Group 3	<i>p</i>
Age [years]	9.98 ± 2.70	9.90 ± 3.72	10.48 ± 2.20	9.66 ± 2.50	0.488
Height [cm]	143.00 (127.25; 157.00)	127.00 ^{ab} (109.00; 146.00)	144.50 ^a (132.38; 160.00)	144.75 ^b (129.63; 157.00)	0.006
Height Z-score	0.29 (−0.74; 1.01)	−1.14 ^{cd} (−3.92; −0.27)	0.35 ^{ce} (−0.41; 0.86)	0.65 ^{de} (−0.11; 1.64)	<0.001
Body weight [kg]	36.00 (25.50; 43.50)	29.00 (17.00; 43.50)	37.50 (30.30; 45.75)	35.75 (26.33; 40.75)	0.155
Body weight Z-score	−0.03 (−0.97; 0.66)	−1.07 ^{fg} (−2.07; 0.27)	0.20 ^f (−0.58; 0.86)	−0.07 ^g (−0.69; 0.88)	0.021
BMI	17.23 (14.86; 20.14)	18.11 (14.72; 21.97)	17.89 (15.47; 20.13)	16.38 (14.54; 18.44)	0.072
BMI Z-score	−0.13 (−1.17; 0.78)	0.12 (−1.38; 1.23)	0.14 (−0.81; 0.93)	−0.41 (−1.19; 0.23)	0.157

Data presented as arithmetic mean ± SD or as median (Q1; Q3), depending on the normality of distribution. Groups were compared using ANOVA or Kruskal–Wallis test with Dunn's post-hoc test. a–h – statistically significant differences for Dunn's post-hoc test (a: *p* = 0.001, b: *p* = 0.002, c, d: *p* < 0.001, e: *p* = 0.048, f: *p* = 0.004, g: *p* = 0.011). BMI – body mass index.

Tab. 1. Anthropometric data for the study population by groups

Vitamin K ₂ [ng/mL]	<i>N</i>	<i>M</i>	<i>SD</i>	<i>MD</i>	<i>Q1</i>	<i>Q3</i>	<i>Min</i>	<i>Max</i>
Total	145	3.85	3.88	2.40	1.30	4.80	0.40	18.10
Group 1	29	4.22	3.86	2.70	1.70	4.90	0.80	15.30
Group 2	48	3.48	3.55	2.05	1.10	4.80	0.60	16.00
Group 1 + 2	77	3.76	3.66	2.40	1.30	4.80	0.60	16.00
Group 3	68	3.94	4.13	2.30	1.28	5.23	0.40	18.10

N – number; *M* – arithmetic mean; *SD* – standard deviation; *MD* – median; *Q1* – first quartile; *Q3* – third quartile; *Min* – minimum; *Max* – maximum.

Tab. 2. Vitamin K₂ levels in the study population by groupsFig. 1. Histogram for vitamin K₂ levels in group 3

After combining groups 1 and 2 into one group and comparing it with group 3 for vitamin K₂ levels, no statistically significant difference was found (*MD* = 0.10; 95% CI: −0.60, 0.60; *p* = 0.997) (Tab. 6).

Decile	Vitamin K ₂ [ng/mL]
1 st	0.90
2 nd	1.00
3 rd	1.37
4 th	1.70
5 th	2.30
6 th	3.10
7 th	4.08
8 th	6.06
9 th	10.75

Tab. 3. Decile distribution of vitamin K₂ levels in group 3

	Group 2	Group 3	<i>MD</i> (95% CI)	<i>p</i>
<i>n</i>	48	68		
Vitamin K ₂ [ng/mL]	2.05 (1.10; 4.80)	2.30 (1.28; 5.23)	−0.25 (−0.80; 0.40)	0.575

Data presented as median (Q1; Q3). *MD* – difference in medians between both groups with 95% confidence level. Mann–Whitney *U* test.

Tab. 4. Mean vitamin K₂ levels in patients with vs. without bone fractures

	Group 1	Group 3	<i>MD</i> (95% CI)	<i>p</i>
<i>n</i>	29	68		
Vitamin K ₂ [ng/mL]	2.70 (1.70; 4.90)	2.30 (1.28; 5.23)	0.40 (−0.50; 1.30)	0.424

Data presented as median (Q1; Q3). *MD* – difference in medians between two groups with 95% confidence level. Mann–Whitney *U* test.

Tab. 5. Comparison of the mean vitamin K₂ levels between groups 1 and 3

	Groups 1 + 2	Group 3	<i>MD</i> (95% CI)	<i>p</i>
<i>n</i>	77	68		
Vitamin K ₂ [ng/mL]	2.40 (1.30; 4.80)	2.30 (1.28; 5.23)	0.10 (−0.60; 0.60)	0.997

Data presented as median (Q1; Q3). *MD* – difference in medians between both groups with 95% confidence level. Mann–Whitney *U* test.

Tab. 6. Mean vitamin K₂ level in patients with bone fractures (combined groups 1 and 2) vs. group 3

This indicates no relationship between vitamin K₂ levels and bone fractures in the study group of children and adolescents (Tab. 6).

DISCUSSION

Vitamin K plays a major role in coagulation, bone metabolism and vascular calcification. Many methods have been developed to measure vitamin K levels in the body. Vitamin K₁ levels are used to determine vitamin K status, with a level of <0.15 µg/L indicating a deficiency. Factors that increase the risk of deficiency include lipid absorption disorders, malnutrition, renal dysfunction and cancer, as well as neonatal and involutional periods⁽⁹⁾.

Children considered healthy and those with fractures without significant bone mineralisation disorders were included

in the study to assess vitamin K₂ levels in the developmental age population. Since eating habits or diet were not assessed, anthropometric measurements were performed in all patients to rule out malnutrition. This allowed to exclude risk factors for vitamin K₂ deficiency in the study population.

Based on the research by van Summeren et al., who were among the first to assess vitamin K in children and found that vitamin K₂ (menaquinones) is more effective than K₁ in the context of bone health^(10,11), a decision was made to determine vitamin K₂ levels in this study. We used the immunoenzymatic ELISA method for this purpose. No reference values for this method were found for the developmental age population in either Polish or foreign literature. Therefore, we created our own reference group, with levels of 0.90–12.46 ng/mL considered normal.

Various indirect and direct methods for determining vitamin K levels have been described in the literature. Their diversity makes it difficult to obtain uniform norms and reference values^(5–9,13–16), which arises from the multiple roles of vitamin K in the pathophysiology of the assessed disorders. In this study, we made an attempt to determine vitamin K₂ levels in children and adolescents with bone fractures since the vast majority of available literature refers to adults with osteoporosis. Since vitamin D preparations and selected forms of vitamin K are used in the prevention of osteoporotic fractures in adults, it seemed reasonable to enquire whether vitamin K should also be used to reduce the risk of bone fractures in children.

Attempts to determine serum vitamin K in adults were undertaken by, among others, Fusaro et al., who assessed data from 387 dialysis patients treated or not with sevelamer. The authors reported mean levels of MK-4 and MK-7 of 0.45 ng/mL (interquartile range 0.15, 0.67) and 1.15 ng/mL (interquartile range 0.53, 1.22), respectively⁽¹⁷⁾. Klapkova et al. measured vitamin K₂ in 350 postmenopausal women (with or without osteoporosis) and found that osteoporotic women had mean levels of 0.890 ± 0.291 ng/mL for MK-4 and 1.002 ± 1.020 ng/mL for MK-7, whereas the mean levels in non-osteoporotic patients were 0.825 ± 0.266 ng/mL and 1.186 ± 1.076 ng/mL, respectively⁽⁵⁾. Vitamin K₂ (menaquinone) occurs in multiple forms. Menaquinones contain an unsaturated side chain with a variable number of prenyl units, which indicates the type of menaquinone, e.g. MK-4 and MK-7 contain four and seven prenyl units, respectively⁽²³⁾. These two forms are most commonly used in the treatment of adult osteoporosis.

Much higher levels of vitamin K were shown by Japanese researchers, which is a consequence of high natto intake in this region. Suhara et al., who assessed osteoporotic and healthy adults, reported MK-7 levels of 6.37 ± 7.45 ng/mL⁽¹⁸⁾. Similar high values, i.e. 3.82 ± 3.11 ng/mL and 16.27 ± 20.58 ng/mL, were also reported by other researchers^(19,20). These discrepancies, which may arise from diverse dietary habits and geographical or cultural differences, generate significant challenges in establishing uniform reference values.

There have been only few studies on the direct determination of vitamin K in children and adolescents.

Kürşat et al. measured vitamin K₂ in healthy Turkish children aged 6 months to 6 years who experienced febrile seizures. Although the researchers used the same method to measure vitamin K₂ levels as we did (ELISA), they obtained significantly higher mean values, i.e. 675.6 ng/mL⁽¹⁴⁾. This may be due to the age difference between the study groups, with a larger proportion of children ≤ 17 years in our study.

The largest group of 1,732 patients aged 1–14 years was assessed by Du and Li, who measured vitamin K₂ levels using HPLC (median level was 0.1 and decreased with age from 0.11 in 1–3-year-olds to 0.08 in 6–14-year-olds). Additionally, these researchers showed a minor negative correlation between age and vitamin K₂ levels ($p = 0.031$, $r = -0.18$)⁽⁸⁾, which was not found in our study.

In one of the latest reports (2024), Chen et al. measured vitamin K using the HPLC method in 807 healthy children aged 0–14 years. The researchers determined reference values for vitamin K₁ for age groups 0–3 years (0.10–1.73 µg/L) and 4–14 years (0.09–4.54 µg/L). The reference range for MK-4 for all children was 0–0.42 µg/L⁽²¹⁾.

Popko et al. conducted their research in a population similar to the one described in our paper, i.e. children from north-eastern Poland who had suffered bone fractures. However, they indirectly measured vitamin K and described its role in the pathophysiology of bone fractures by assessing two forms of osteocalcin using the ELISA approach⁽²²⁾.

The cited research shows that the assessment of vitamin K levels is a difficult and complex process that depends on multiple factors, including the measurement technique and purpose, as well as the study group. Additionally, Fusaro et al. emphasised that the measurement of vitamin K may be challenging due to lipid interference and its low serum levels, as well as its nonpolar properties, especially in the case of some forms of MK⁽¹⁾.

CONCLUSIONS

Vitamin K₂ levels in the study population of children and adolescents with a history of bone fractures were within the reference range for this age group, which suggests that bone fractures were not associated with a deficiency of this vitamin.

Conflict of interest

The authors do not report any financial or personal connections with other persons or organisations which might negatively affect the contents of this publication and/or claim authorship rights to this publication.

Author contributions

Original concept of study: MP, EJP. Collection, recording and/or compilation of data: MP, EW. Analysis and interpretation of data; writing of manuscript: MP. Critical review of manuscript; final approval of manuscript: EJP.

References

1. Fusaro M, Galliemi M, Rizzo MA et al.: Vitamin K plasma levels determination in human health. *Clin Chem Lab Med* 2017; 55: 789–799.
2. Mager DR, McGee PL, Furuya KN et al.: Prevalence of vitamin K deficiency in children with mild to moderate chronic liver disease. *J Pediatr Gastroenterol Nutr* 2006; 42: 71–76.
3. Stroppe J, Lovell G, Heubi J: Prevalence of subclinical vitamin K deficiency in cholestatic liver disease. *J Pediatr Gastroenterol Nutr* 2009; 49: 78–84.
4. Vermeer C: Vitamin K: the effect on health beyond coagulation – an overview. *Food Nutr Res* 2012; 56.
5. Tsugawa N, Shiraki M, Suhara Y et al.: Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. *Am J Clin Nutr* 2006; 83: 380–386.
6. Klappkova E, Cepova J, Dunovska K et al.: Determination of vitamins K₁, MK-4, and MK-7 in human serum of postmenopausal women by HPLC with fluorescence detection. *J Clin Lab Anal* 2018; 32: e22381.
7. Volkan B, Fettah A, İşlek A et al.: Bone mineral density and vitamin K status in children with celiac disease: is there a relation? *Turk J Gastroenterol* 2018; 29: 215–220.
8. Du CX, Li N: [Serum vitamin K₂ level and its association with bone metabolism markers in 1 732 children]. *Zhongguo Dang Dai Er Ke Za Zhi* 2022; 24: 1130–1135.
9. Card DJ, Gorska R, Harrington DJ: Laboratory assessment of vitamin K status. *J Clin Pathol* 2020; 73: 70–75.
10. Karpiński M, Popko J, Maresz K et al.: Roles of vitamins D and K, nutrition, and lifestyle in low-energy bone fractures in children and young adults *J Am Coll Nutr* 2017; 36: 399–412.
11. van Summeren MJ, van Coeverden SC, Schurgers LJ et al.: Vitamin K status is associated with childhood bone mineral content. *Br J Nutr* 2008; 100: 852–858.
12. Merckaert S, Chaibi E, Meriem S et al.: Epidemiology of pediatric upper extremity fractures in a tertiary care center in Switzerland. *Pediatr Emerg Care* 2021; 37: e825–e835.
13. Moore AE, Kim EJ, Dulnoan D et al.: Serum vitamin K₁ (phylloquinone) is associated with fracture risk and hip strength in post-menopausal osteoporosis: a cross-sectional study. *Bone* 2020; 141: 115630.
14. Kürşat BC, Yasemin K, Gül GM et al.: The evaluation of vitamin K status in children with febrile seizure. *Balkan Med J* 2021; 38: 116–120.
15. Nie S, Yang L, Feng J et al.: Reference range of vitamin K evaluating indicators in Chinese childbearing women. *Nutrients* 2023; 15: 1977.
16. Bultynck C, Munim N, Harrington DJ et al.: Prevalence of vitamin K deficiency in older people with hip fracture. *Acta Clin Belg* 2020; 75: 136–140.
17. Fusaro M, Cozzolino M, Plebani M et al.: Vitamin K levels, vascular calcifications, and vertebral fractures in hemodialysis patients: results from the VIKI study. *J Bone Miner Res* 2021; 36: 500–509.
18. Suhara Y, Kamao M, Tsugawa N et al.: Method for the determination of vitamin K homologues in human plasma using high-performance liquid chromatography-tandem mass spectrometry. *Anal Chem* 2005; 77: 757–763.
19. Kaneki M, Hedges SJ, Hosoi T et al.: Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K₂; possible implications for hip-fracture risk. *Nutrition* 2001; 17: 315–321.
20. Kamao M, Suhara Y, Tsugawa N et al.: Determination of plasma vitamin K by high-performance liquid chromatography with fluorescence detection using vitamin K analogs as internal standards. *J Chromatogr B* 2005; 816: 41–48.
21. Chen YQ, Fang SF, Liu X et al.: [Establishing reference ranges of serum vitamin K in healthy children]. *Zhonghua Er Ke Za Zhi* 2024; 62: 847–852.
22. Popko J, Karpiński M, Chojnowska S et al.: Decreased levels of circulating carboxylated osteocalcin in children with low energy fractures: a pilot study. *Nutrients* 2018; 10: 734.
23. Oldenburg J, Marinova M, Müller-Reible C et al.: The vitamin K cycle. *Vitam Horm* 2008; 78: 35–62.